title: G-CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function?
abstract: Severe alcoholic hepatitis is a life-threatening liver disease. Although corticosteroid treatment is recommended and improves survival, mortality remains high and 35% of patients die within 6 months. There is no available medical treatment for patients who do not respond to corticosteroids. A new randomized pilot trial shows that the administration of the cytokine granulocyte colony-stimulating factor (G-CSF) improves liver function and 3-month survival in patients with severe alcoholic hepatitis. These results suggest a new therapeutic approach for severe alcoholic hepatitis.
authors.affiliation: 1] Inserm U1149, Centre de Recherche sur l'Inflammation (CRI), Paris, France [2] UMR_S 1149, Faculté de Médecine, Université Paris-Diderot, Paris 7, Paris, France [3] Département Hospitalo-Universitaire (DHU) UNITY, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France [4] Laboratoire d'Excellence (Labex) Inflamex, PRES Sorbonne Paris Cité, Paris, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Moreau
authors.affiliation: 1] Département Hospitalo-Universitaire (DHU) UNITY, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France [2] Inserm U970, Paris Cardiovascular Research Center-PARCC, Paris, France [3] UMR-S970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
authors.forename: Pierre-Emmanuel
authors.initials: PE
authors.lastname: Rautou
mesh_terms: D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006519:Hepatitis, Alcoholic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009504:Neutrophils
chemical_list: D016179:Granulocyte Colony-Stimulating Factor